The fight against breast cancer is more critical than ever, especially as breakthroughs in blood testing are opening new doors for early detection and personalized treatment. But here's where it gets controversial: could a simple blood test truly predict how well an individual with advanced breast cancer will respond to therapy? And how might this shift the landscape of cancer care forever?
We often hear about breast cancer, yet many of us don’t give it the attention it truly deserves. This silence is problematic because breast cancer isn’t just a distant issue affecting “other people”—it’s a very real threat close to home. Globally, in 2022 alone, approximately 2.3 million women received a breast cancer diagnosis, and around 670,000 lost their lives due to the disease. Meanwhile, in India, breast cancer has quietly become the leading cancer among women, surpassing other types that once topped the charts. Every few minutes, an Indian woman learns she has this disease, and tragically, many are only diagnosed when the cancer has already advanced, making treatment much more difficult.
So, why does raising awareness about breast cancer matter so much? First, early detection is critical because catching the disease early can significantly improve treatment success rates and survival chances. When breast cancer is diagnosed at an early stage, therapies are more effective, and outcomes tend to be much better. Second, increasing awareness helps to reduce fear and stigma. Many women tend to ignore warning signs—like lumps, changes in nipple appearance, or unusual discharges—because they feel embarrassed, afraid, or unsure about what the symptoms mean. Third, there’s a big gap between knowing about breast cancer and actually acting on that knowledge. While most women have heard the term “breast cancer,” far fewer undertake regular screenings or know how to perform self-examinations properly.
The good news is that advances in detection and treatment are making a real difference. Today, the fight against breast cancer isn’t limited to traditional mammograms. Newer methods include blood tests, genetic screenings, and sophisticated imaging techniques that can identify issues much earlier. Additionally, treatment options have evolved greatly. Targeted therapies and personalized medicine now allow doctors to customize treatment plans based on each patient’s unique genetic makeup, moving away from the one-size-fits-all approach.
Recently, researchers from The Institute of Cancer Research in London have uncovered a promising development: a blood test capable of predicting how patients with advanced breast cancer will respond to targeted therapies. Their groundbreaking findings, published in the journal Clinical Cancer Research, analyze blood samples to detect circulating tumor DNA (ctDNA). This DNA is shed into the bloodstream by cancer cells, providing valuable information about the tumor’s genetic profile.
The study revealed a strong link between the levels of ctDNA at the start of treatment and how well patients responded. Additionally, changes in ctDNA levels after about four weeks, which corresponds to one treatment cycle, can give doctors early insights into whether the therapy is working.
Dr. Arun Kumar Goel, a leading expert in surgical oncology from Andromeda Cancer Hospital, explains: “Circulating tumor DNA contains fragments of genetic material released from cancer cells that circulate in the blood. By measuring these fragments, physicians can assess genetic changes associated with the tumor. Tracking the amount of ctDNA over time helps determine if a patient’s disease is responding to treatment—decreasing levels hint at a positive response, while an increase can indicate resistance or progression—even before imaging scans like MRI or PET can detect changes.”
However, Dr. Goel emphasizes that low levels of ctDNA do not guarantee a cure. “While low or undetectable ctDNA suggests that the treatment is effective, it does not definitively mean the disease is gone. Some tumors shed only tiny amounts of ctDNA or may be hidden in areas like the brain, where current tests struggle to detect them. Therefore, ctDNA should be seen as a marker of risk or response, rather than a clear predictor of future remission.”
He also highlights that ctDNA testing could reduce the need for invasive biopsies in certain situations, such as monitoring treatment efficacy or identifying resistance mutations, especially when tissue samples are difficult to obtain. Yet, he stresses that it cannot replace traditional biopsies altogether. “Biopsies remain essential for initial diagnosis, tumor grading, and comprehensive analysis, providing invaluable information that blood tests currently cannot match.”
In summary, this innovative approach represents a significant leap forward in personalized cancer care, offering hope for more precise, less invasive monitoring of treatment responses. Yet, it’s crucial to continue discussing its limitations and implications. Do you believe blood tests like these will eventually replace conventional biopsies altogether? Or should they complement existing methods? Share your thoughts below—your opinion could help shape future cancer care strategies.
